Urologische Klinik

Krankenhausstraße 12
91054 Erlangen

Untergeordnete Organisationseinheiten

Lehrstuhl für Urologie

Publikationen (Download BibTeX)

Go to first page Go to previous page 1 von 7 Go to next page Go to last page

Sikic, D., Wirtz, R.M., Wach, S., Dyrskjot, L., Erben, P., Bolenz, C.,... Keck, B. (2019). Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. Translational Oncology, 12(4), 661-668. https://dx.doi.org/10.1016/j.tranon.2019.01.005
Rot, S., Kaune, T., Taubert, H., Greither, T., Kotrba, J., Guettler, A.,... Kappler, M. (2019). Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients. Bmc Cancer, 19. https://dx.doi.org/10.1186/s12885-019-5327-8
Stoehr, C.G., Steffens, S., Polifka, I., Jung, R., Kahlmeyer, A., Ivanyi, P.,... Taubert, H. (2019). Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients. Scientific Reports, 9. https://dx.doi.org/10.1038/s41598-018-38254-3
Goebell, P., Hermann, E., Kube, U., Doehn, C., Marschner, N., Dietel, A.,... Bergmann, L. (2019). Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study. Oncology Research and Treatment, 42(1-2), 57-66. https://dx.doi.org/10.1159/000494278
Breyer, J., Wirtz, R.M., Erben, P., Rinaldetti, S., Worst, T.S., Stoehr, R.,... Otto, W. (2019). FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. Bju International, 123(1), 187-196. https://dx.doi.org/10.1111/bju.14525
Eckstein, M., Erben, P., Kriegmair, M.C., Worst, T.S., Weiss, C.-A., Wirtz, R.M.,... Erlmeier, F. (2019). Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European journal of cancer, 106, 234-243. https://dx.doi.org/10.1016/j.ejca.2018.11.007
Eckstein, M., Wirtz, R.M., Pfannstil, C., Wach, S., Stoehr, R., Breyer, J.,... Erben, P. (2018). A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 9(19), 15001-15014. https://dx.doi.org/10.18632/oncotarget.24531
Wach, S., Weigelt, K., Michalke, B., Lieb, V., Stoehr, R., Keck, B.,... Chaudhri, A. (2018). Diagnostic potential of major and trace elements in the serum of bladder cancer patients. Journal of Trace Elements in Medicine and Biology, 46, 150-155. https://dx.doi.org/10.1016/j.jtemb.2017.12.010
Eckstein, M., Wirtz, R., Pfannstil, C., Wach, S., Stoehr, R., Breyer, J.,... Erben, P. (2018). A multicenter comparison of PD-L1 protein and mRNA expression in urothelial bladder cancer by immunohistochemistry and RT-qPCR (Checkpoint-Typer(C)): A round robin test by the BRIDGE-Consortium Germany. (pp. 81-81).
Lieb, V., Weigelt, K., Scheinost, L., Fischer, K., Greither, T., Marcou, M.,... Wach, S. (2018). Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients. Oncotarget, 9(12), 10402-10416. https://dx.doi.org/10.18632/oncotarget.23781
Schostak, M., Koenig, F., Boegemann, M., Goebell, P., Hammerer, P., Machtens, S.,... Heidenreich, A. (2018). Advanced Prostate Cancer Consensus Conference 2017. Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts. Urologe, 57(7), 813-820. https://dx.doi.org/10.1007/s00120-018-0680-9
Schmidt, S., Kunath, F., & Wullich, B. (2018). UroEvidence opens new Call for Applications. Urologe, 57(12), 1488-1489. https://dx.doi.org/10.1007/s00120-018-0812-2
Rot, S., Taubert, H., Bache, M., Greither, T., Wuerl, P., Holzhausen, H.-J.,... Kappler, M. (2018). Low HIF-1 alpha and low EGFR mRNA Expression Significantly Associate with Poor Survival in Soft Tissue Sarcoma Patients; the Proteins React Differently. International Journal of Molecular Sciences, 19(12). https://dx.doi.org/10.3390/ijms19123842
Eckstein, M., Jung, R., Weigelt, K., Sikic, D., Stoehr, R., Geppert, C.,... Taubert, H. (2018). Piwi-like 1 and-2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients. Scientific Reports, 8. https://dx.doi.org/10.1038/s41598-018-35637-4
Burger, M., Schwaibold, H., Goebell, P., & Grimm, M.-O. (2018). Non-invasive bladder cancer. Onkologe, 24(1), 23-31.
Greither, T., Fischer, K., Theil, G., Marcou, M., Holzhausen, H.-J., Weigelt, K.,... Lieb, V. (2018). Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival. Cancer Management and Research , 10, 4173-4180. https://dx.doi.org/10.2147/CMAR.S172069
Boegemann, M., Bedke, J., Schostak, M., Welslau, M., Hering-Schubert, C., Wolf, T.,... Goebell, P. (2018). Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL. (pp. 201-202).
Olbert, P., Goebell, P., & Hegele, A. (2018). Follow-up of bladder cancer. The right examinations at the right time. Urologe, 57(6), 693-701. https://dx.doi.org/10.1007/s00120-018-0641-3
Kahlmeyer, A., Wullich, B., & Wiedemann, A. (2018). Geriatric Urology. Urologe, 57(4), 387-388. https://dx.doi.org/10.1007/s00120-018-0621-7
Black, P.C., Goebell, P., Kamat, A.M., Nawroth, R., & Schmitz-Draeger, B.J. (2018). Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urologic Oncology-Seminars and Original Investigations, 36(9), 403-404. https://dx.doi.org/10.1016/j.urolonc.2017.11.006

Zusätzliche Publikationen (Download BibTeX)

Ihrig, A., Renner, T., Muck, T., Maatz, P., Borkowetz, A., Keck, B.,... Huber, J. (2019). Online support groups offer low-threshold backing for family and friends of patients with prostate cancer. European Journal of Cancer Care, 28(2). https://dx.doi.org/10.1111/ecc.12982
Huber, J., Muck, T., Maatz, P., Keck, B., Enders, P., Maatouk, I., & Ihrig, A. (2018). Face-to-face vs. online peer support groups for prostate cancer: A cross-sectional comparison study. Journal of Cancer Survivorship, 12(1), 1-9. https://dx.doi.org/10.1007/s11764-017-0633-0
Tselis, N., Prott, F.J., Ott, O., Weiss, C., & Roedel, C. (2018). Radiochemotherapy for invasive bladder cancer : An update. Urologe, 57(6), 679-685. https://dx.doi.org/10.1007/s00120-018-0628-0
Zengerling, F., Kunath, F., Jensen, K., Ruf, C., Schmidt, S., & Spek, A. (2017). Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. Urologic Oncology-Seminars and Original Investigations. https://dx.doi.org/10.1016/j.urolonc.2017.06.047
Pinart, M., Kranz, J., Jensen, K., Proctor, T., Naber, K., Kunath, F.,... Schmidt, S. (2017). Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis. International Journal of Infectious Diseases, 58, 96-109. https://dx.doi.org/10.1016/j.ijid.2017.03.012
Schmidt, S., Kunath, F., & Kroeger, N. (2015). Immunotherapy for advanced renal cell cancer. Urologe, 54(5), 716-20. https://dx.doi.org/10.1007/s00120-015-3825-0
Hager, B., Kraywinkel, K., Keck, B., Katalinic, A., Meyer, M., Zeissig, S.R.,... Huber, J. (2015). Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011. Radiotherapy and Oncology, 115(1), 90-5. https://dx.doi.org/10.1016/j.radonc.2015.02.024
Kunath, F., Spek, A., Jensen, K., Zengerling, F., & Schmidt, S. (2015). Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - protocol for a systematic review. Systematic Reviews, 4, 182. https://dx.doi.org/10.1186/s13643-015-0167-3

Zuletzt aktualisiert 2016-05-05 um 04:58